Genmab Announces HuMax-CD32b Pre-Clinical Program

Summary:  Genmab has announced a new-preclinical antibody program called        
HuMax-CD32b.                                                                    

Copenhagen, Denmark; January 4, 2008 - Genmab A/S (OMX: GEN) announced today a  
new pre-clinical antibody program called HuMax-CD32b(TM).  This fully human     
IgG1,k antibody  targets the CD32b receptor found on immune cells and           
hematological tumors.  HuMax-CD32b may have therapeutic potential in the        
treatment of B-cell chronic lymphocytic leukemia, small lymphocytic lymphoma,   
Burkitt's lymphoma, follicular lymphoma and diffuse large B-cell lymphoma.      

The lead candidate for HuMax-CD32b was selected from a panel of over 60         
antibodies based on its excellent selectivity and binding ability for the CD32b 
target and potent triggering of the immune system killing mechanism             
antibody-dependent cellular cytotoxicity (ADCC). The antibody was highly        
effective in suppressing tumor growth in in vivo mouse tumor models in which    
tumor growth was monitored by highly sensitive bioluminescence imaging.         

In animal models, HuMax-CD32b has been shown to induce impressive anti-tumor    
responses. The CD32b receptor has an inhibitory role on immune cells and        
blockade of CD32b has been documented to strongly potentiate the therapeutic    
effects of other anti-tumor antibodies. An antibody targeting CD32b may thus be 
attractive for combination therapy with other antibodies.                       

“We believe HuMax-CD32b has great potential as a cancer therapeutic, both       
because of its impressive anti-tumor activity, and the potential for combination
with other therapeutic antibodies, such as antibodies directed to CD20 or CD38.”
said Prof. Jan G. J. van de Winkel, Ph.D., Chief Scientific Officer at Genmab   
A/S.                                                                            

About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using unique,       
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.   
As Genmab advances towards a commercial future, we remain committed to our      
primary goal of improving the lives of patients who are in urgent need of new   
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 01/2008                                              

###